Cencora (COR)

• Market cap: $46.8B
• 1 day: 0.48%
• 5 days: 2.39%
• 1 month: 6.33%
• 3 months: 2.72%
• 6 months: 7.50%
• Year to date: 7.70%
• 1 year: 10.67%
• 5 years: 35.30%
• 10 years: 113.62%
• Sector: Healthcare
• Industry: Drugs, Proprietaries & Druggists Sundries

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

107% more call options, than puts

Call options by funds: $1.7B | Put options by funds: $819M

43% more first-time investments, than exits

New positions opened: 129 | Existing positions closed: 90

20% more repeat investments, than reductions

Existing positions increased: 456 | Existing positions reduced: 380

2% more funds holding

Funds holding: 1,115 [Q2] → 1,138 (+23) [Q3]

5% less capital invested

Capital invested by funds: $46.2B [Q2] → $44.1B (-$2.18B) [Q3]

3.54% less ownership

Funds ownership: 102.93% [Q2] → 99.39% (-3.54%) [Q3]

17% less funds holding in top 10

Funds holding in top 10: 18 [Q2] → 15 (-3) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $237 2% downside
• Avg. target: $278 15% upside
• High target: $292 21% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Wells Fargo Eric Luebchow 64% 1-year accuracy 27 / 42 met price target	2% downside $237	Equal-Weight Maintained	13 Dec 2024
Baird David Rodgers 44% 1-year accuracy 11 / 25 met price target	21% upside $292	Outperform Maintained	7 Nov 2024
UBS Kevin Caliendo 65% 1-year accuracy 11 / 17 met price target	18% upside $285	Buy Maintained	7 Nov 2024
Barclays Stephanie Davis 38% 1-year accuracy 5 / 13 met price target	20% upside $290	Overweight Maintained	7 Nov 2024
Evercore ISI Group John Belton 67% 1-year accuracy 2 / 3 met price target	18% upside $285	Outperform Maintained	7 Nov 2024